Avani C Modi1, Shanna M Guilfoyle, Joseph Rausch. 1. Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. avani.modi@cchmc.org
Abstract
OBJECTIVE: To report acceptability, feasibility, and preliminary efficacy from a randomized controlled trial of a family-tailored adherence intervention (AI) targeting nonadherence to antiepileptic drugs in pediatric new-onset epilepsy. METHOD:30 children with new-onset epilepsy (7.2 ± 3.1 years old, 47% male) and their caregivers participated. At baseline, participants were given adherence electronic monitors. After a 1-month run-in period, participants with good adherence (≥90%) were monitored. Participants with adherence <90% were randomized to the AI or Treatment-As-Usual (TAU) group. The AI group received four adherence promotion intervention sessions over >2 months. Follow-up adherence data were collected. RESULTS:8 families were randomized (AI, n = 4; TAU, n = 4). Families perceived AI to be feasible and acceptable. Preliminary results demonstrated that the AI group had improved adherence from baseline to post-test. CONCLUSIONS: A family-tailored AI appears promising and needs to be tested with a larger pediatric epilepsy sample.
RCT Entities:
OBJECTIVE: To report acceptability, feasibility, and preliminary efficacy from a randomized controlled trial of a family-tailored adherence intervention (AI) targeting nonadherence to antiepileptic drugs in pediatric new-onset epilepsy. METHOD: 30 children with new-onset epilepsy (7.2 ± 3.1 years old, 47% male) and their caregivers participated. At baseline, participants were given adherence electronic monitors. After a 1-month run-in period, participants with good adherence (≥90%) were monitored. Participants with adherence <90% were randomized to the AI or Treatment-As-Usual (TAU) group. The AI group received four adherence promotion intervention sessions over >2 months. Follow-up adherence data were collected. RESULTS: 8 families were randomized (AI, n = 4; TAU, n = 4). Families perceived AI to be feasible and acceptable. Preliminary results demonstrated that the AI group had improved adherence from baseline to post-test. CONCLUSIONS: A family-tailored AI appears promising and needs to be tested with a larger pediatric epilepsy sample.
Authors: Christopher G McCusker; Patrick John Kennedy; Jennifer Anderson; Elaine M Hicks; Donncha Hanrahan Journal: Dev Med Child Neurol Date: 2002-10 Impact factor: 5.449
Authors: C E Begley; M Famulari; J F Annegers; D R Lairson; T F Reynolds; S Coan; S Dubinsky; M E Newmark; C Leibson; E L So; W A Rocca Journal: Epilepsia Date: 2000-03 Impact factor: 5.864
Authors: Melinda A Nolan; M Antoinette Redoblado; Suncica Lah; Mark Sabaz; John A Lawson; Anne M Cunningham; Andrew F Bleasel; Ann M E Bye Journal: Epilepsy Res Date: 2003-02 Impact factor: 3.045
Authors: Erik de Klerk; Désirée van der Heijde; Robert Landewé; Hille van der Tempel; John Urquhart; Sjef van der Linden Journal: J Rheumatol Date: 2003-01 Impact factor: 4.666
Authors: Kelly D Coyne; Katherine A Trimble; Ashley Lloyd; Laura Petrando; Jennie Pentz; Kari Van Namen; Andrea Fawcett; Catherine M Laing Journal: J Pediatr Oncol Nurs Date: 2019-04-04 Impact factor: 1.636
Authors: Rachelle R Ramsey; Kristin Loiselle; Joseph R Rausch; Jordan Harrison; Avani C Modi Journal: Epilepsy Behav Date: 2016-03-12 Impact factor: 2.937
Authors: Rosa Michaelis; Venus Tang; Janelle L Wagner; Avani C Modi; William Curt LaFrance; Laura H Goldstein; Tobias Lundgren; Markus Reuber Journal: Cochrane Database Syst Rev Date: 2017-10-27